Screening for pulmonary arterial hypertension in systemic sclerosis
Open Access
- 31 July 2019
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 28 (153) , 190023
Abstract
Pulmonary arterial hypertension (PAH) is a dreaded complication of systemic sclerosis (SSc) that occurs in ∼10% of patients. Most individuals present with severe symptoms, significant functional impairment and severe haemodynamics at diagnosis, and survival after PAH diagnosis is poor. Therefore, early diagnosis through systematic screening of asymptomatic patients has the potential to identify PAH at an early stage. Current evidence suggests that early diagnosis and treatment of PAH in patients with SSc may lead to better clinical outcomes. Annual screening may include echocardiography, but this can miss some patients due to suboptimal visualisation or insufficient tricuspid regurgitation. Other options for screening include the DETECT algorithm or the use of a combination of pulmonary function testing (forced vital capacity/diffusing capacity of the lung for carbon monoxide ratio) and N-terminal-pro-brain natriuretic peptide levels. Symptomatic patients, those with an elevated tricuspid regurgitation velocity on echocardiogram with or without secondary echocardiographic features of PAH, and those who screen positive on the DETECT or other pulmonary function test algorithms should undergo right heart catheterisation. Exercise echocardiography or cardiopulmonary exercise testing, nailfold capillaroscopy and molecular biomarkers are promising but, as yet, unproven potential options. Future screening studies should employ systematic catheterisation to define the true predictive values for PAH.Keywords
This publication has 101 references indexed in Scilit:
- The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort studyArthritis Research & Therapy, 2013
- Relevance of Partitioning DLCO to Detect Pulmonary Hypertension in Systemic SclerosisPLOS ONE, 2013
- Stress Doppler Echocardiography in Systemic Sclerosis: Evidence for a Role in the Prediction of Pulmonary HypertensionArthritis & Rheumatism, 2013
- N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control studyArthritis Research & Therapy, 2012
- Hemodynamic Predictors of Survival in Scleroderma-related Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patientsAnnals of the Rheumatic Diseases, 2009
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Accuracy of Doppler Echocardiography in the Hemodynamic Assessment of Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control studyRespiratory Research, 2008
- Changes in causes of death in systemic sclerosis, 1972–2002Annals of the Rheumatic Diseases, 2007